Bio/Pharma News

Jul 27, 2018
By Pharmaceutical Technology Editors
Pfizer will invest nearly half a billion dollars to build a sterile injectable facility in Michigan.
Jul 27, 2018
By Pharmaceutical Technology Editors
Novartis is set to partner with MorphoSys and Galapagos in a deal worth up to $1.1 billion to develop and commercialize their joint investigational, fully human, IgG1 monoclonal antibody (mAb) directed against the target IL-17C.
Jul 26, 2018
By Pharmaceutical Technology Editors
The acquisition would combine Sangamo’s ex vivo gene-editing capabilities with TxCell's regulatory T-cell (Treg) expertise to create chimeric antigen receptor (CAR)-Treg therapies.
Jul 19, 2018
By Pharmaceutical Technology Editors
The agency has issued a warning letter for cGMP violations at a drug manufacturing facility in Ahmedabad, India, that Baxter gained through its acquisition of Claris Injectables.
Jul 19, 2018
By Pharmaceutical Technology Editors
The company has run into a snag in producing Kymriah for the diffuse large B-cell lymphoma patient population, the second indication for which the therapy was recently approved by FDA.
Jul 18, 2018
By Pharmaceutical Technology Editors
CELLforCURE will produce cancer CAR-T treatments for Novartis at a manufacturing facility in Les Ulis (Essonne), France.
Jul 17, 2018
By Pharmaceutical Technology Editors
Moderna’s new manufacturing plant in Norwood, MA gives the company capacity for preclinical and Phase I and II clinical manufacturing for its mRNA development candidates, including personalized cancer vaccines.
Jul 16, 2018
By Pharmaceutical Technology Editors
Otsuka Pharmaceutical will acquire Visterra, a clinical-stage biotechnology company focused on developing antibody-based therapies, for approximately $430 million.
Jul 11, 2018
By Pharmaceutical Technology Editors
Pfizer creates separate business units for innovator medicines, generic drugs, and consumer products.
Jul 11, 2018
By Pharmaceutical Technology Editors
The company has received clearance from the United States Federal Trade Commission for the proposed acquisition of Shire, a deal valued at $62 billion.
native1_300x100
lorem ipsum